UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
UroGen Pharma (Nasdaq: URGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference, held June 8–10, 2026.
Management is scheduled for a fireside chat and 1x1 investor meetings on June 10, 2026 at 8:40 AM ET in Miami Beach, FL, with a webcast and 90-day replay.
Positive
- None.
Negative
- None.
News Market Reaction – URGN
In the Jun 2 session, URGN declined 1.81%, reflecting a mild negative market reaction. Argus tracked a peak move of +9.2% during that session. Argus tracked a trough of -2.0% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Phase 3 UTOPIA data | Positive | -3.0% | UGN-103 showed 94.5% six‑month DOR in recurrent LG-IR-NMIBC Phase 3 trial. |
| May 13 | ENVISION update | Positive | +3.8% | ZUSDURI ENVISION data showed 64.5% 36‑month DOR with median not yet reached. |
| May 07 | Investor conferences | Neutral | +1.3% | Announced participation in three May 2026 investor conferences with webcast access. |
| May 06 | Q1 2026 earnings | Positive | +10.2% | Q1 2026 revenue reached $51.0M with strong ZUSDURI and JELMYTO contributions. |
| Apr 29 | Earnings date notice | Neutral | -3.2% | Announced May 6, 2026 earnings release and conference call logistics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive updates (earnings, key clinical data) often saw aligned price gains, but one major clinical win drew a short-term selloff, indicating occasionally contrarian reactions to good news.
Over the past months, URGN reported strong Q1 2026 financials with revenue of $51.0M and notable growth from ZUSDURI and JELMYTO, which drove a 10.16% price gain. Subsequent data from the Phase 3 UTOPIA trial for UGN-103 showed a 94.5% six‑month duration of response, yet shares fell 3.03%, contrasting with the positive fundamentals. The company also delivered encouraging long‑term ENVISION data and actively engaged investors through multiple conferences, including prior May 2026 events, framing the new Goldman Sachs conference appearance as continued investor outreach rather than a new clinical or financial catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026.
Goldman Sachs 47th Annual Global Healthcare Conference
| Date / Time: | June 10, 2026, at 8:40 AM ET |
| Format: | Fireside chat and 1x1 investor meetings |
| Location: | Miami Beach, FL |
| Webcast Link: | here |
The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is approved for adult patients with recurrent LG-IR-NMIBC. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X, @UroGenPharma.
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083
